Interactions of inhibitor molecules with the human CYP2E1 enzyme active site

被引:21
作者
Martikainen, Laura E. [1 ]
Rahnasto-Rilla, Minna [1 ]
Neshybova, Silvie [1 ]
Lahtela-Kakkonen, Maija [1 ]
Raunio, Hannu [1 ]
Juvonen, Risto O. [1 ]
机构
[1] Univ Eastern Finland, Sch Pharm, Kuopio 70211, Finland
关键词
CoMFA; CYP2E1; Inhibition; Quantitative structure-activity relationship; HUMAN CYTOCHROME-P450 2E1; RAT-LIVER; P450; 2E1; ACID; METABOLISM; BINDING; IDENTIFICATION; CONSTRUCTION; VALIDATION; PREDICTION;
D O I
10.1016/j.ejps.2012.09.018
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
CYP2E1 is an important enzyme oxidizing ethanol as well as several drugs and other xenobiotics in the human liver. We determined the inhibition potency of structurally diverse compounds against human CYP2E1, and analyzed their interactions with the enzyme active site by molecular docking and 3D-QSAR approaches. The IC50 values for the tested compounds varied from 1.4 mu M for gamma-undecanolactone to over 46 mM for glycerol. This data set was used to create a comparative molecular field analysis (CoMFA) model. The most important interactions for binding of inhibitors were identified by docking and key features for inhibitors were characterized via the COMFA model. Since the active site of CYP2E1 is flexible, long chain lactones and alkyl alcohols fitted best into the larger open form while the other compounds fitted better in the smaller closed form of the active site. Electrostatic interactions near the Thr(303) residue proved to be important for inhibition of the enzyme activity. Thus, docking analysis and the predictive CoMFA model proved to be efficient tools for revealing interactions between inhibiting compounds and CYP2E1. These approaches can be used to analyze CYP2E1-mediated metabolism and drug interactions in the development of new chemical entities. (C) 2012 Elsevier B.V. All rights reserved.
引用
收藏
页码:996 / 1005
页数:10
相关论文
共 45 条
[1]  
Adas F, 1998, J LIPID RES, V39, P1210
[2]   Dilinoleoylphosphatidylcholine decreases ethanol-induced cytochrome P4502E1 [J].
Aleynik, MK ;
Lieber, CS .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2001, 288 (04) :1047-1051
[3]   Cytochromes P450 and metabolism of xenobiotics [J].
Anzenbacher, P ;
Anzenbacherová, E .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2001, 58 (5-6) :737-747
[4]   The cytochrome P-450 isoenzyme CYP2E1 in the biological processing of industrial chemicals: consequences for occupational and environmental medicine [J].
Bolt, HM ;
Roos, PH ;
Thier, R .
INTERNATIONAL ARCHIVES OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH, 2003, 76 (03) :174-185
[5]   Acetone catabolism by cytochrome P450 2E1: Studies with CYP2E1-null mice [J].
Bondoc, FY ;
Bao, ZP ;
Hu, WY ;
Gonzalez, FJ ;
Wang, YY ;
Yang, CS ;
Hong, JY .
BIOCHEMICAL PHARMACOLOGY, 1999, 58 (03) :461-463
[6]   VALIDATION OF THE GENERAL-PURPOSE TRIPOS 5.2 FORCE-FIELD [J].
CLARK, M ;
CRAMER, RD ;
VANOPDENBOSCH, N .
JOURNAL OF COMPUTATIONAL CHEMISTRY, 1989, 10 (08) :982-1012
[7]  
Devore N.M., 2011, FEBS J
[8]   REPLACEMENT OF THR-303 OF P450 2E1 WITH SERINE MODIFIES THE REGIOSELECTIVITY OF ITS FATTY-ACID HYDROXYLASE-ACTIVITY [J].
FUKUDA, T ;
IMAI, Y ;
KOMORI, M ;
NAKAMURA, M ;
KUSUNOSE, E ;
SATOUCHI, K ;
KUSUNOSE, M .
JOURNAL OF BIOCHEMISTRY, 1993, 113 (01) :7-12
[9]  
Holtje HD., 2008, MOL MODELING BASIC P
[10]  
Hutzler JM, 2005, CURR OPIN DRUG DISC, V8, P51